Novo Nordisk India Slashes Wegovy Price By 37% To Stay Ahead Of Rivals? Vikrant Shrotriya Answers

In an exclusive conversation with Business Today’s Neetu Chandra, Vikrant Shrotriya, Managing Director of Novo Nordisk India, discusses how the company is leading India’s obesity treatment revolution. Amid intensifying competition from Eli Lilly’s Mounjaro, he emphasizes that Novo Nordisk is driven by purpose, not rivalry. Shrotriya highlights the recent 37% price cut for wegovy, aimed at improving patient accessibility, and the company’s partnership with Emcure to expand reach across India. With over 250 million people living with obesity, he says this is just the tip of the iceberg—and Novo Nordisk’s mission is clear: to bend the curve of obesity through innovation, collaboration, and accessibility.